Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGED1 small interfering RNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
MAGED1 small interfering RNA is an experimental RNA interference (RNAi) agent designed to silence the expression of the Melanoma Antigen Gene Family, Member D1 (MAGED1). MAGED1 is a multi-functional protein involved in cell cycle regulation and cell death, and it plays a critical role in the repair of DNA double-strand breaks via the homologous recombination repair (HRR) pathway. Suppression of MAGED1 leads to homologous recombination deficiency (HRD), a state that significantly increases the sensitivity of cancer cells to platinum-based chemotherapies (such as cisplatin) and poly (ADP-ribose) polymerase (PARP) inhibitors (such as olaparib and niraparib). This therapeutic strategy is particularly relevant for triple-negative breast cancer (TNBC) and BRCA1/2-mutant breast cancers, where enhancing the DNA damage response vulnerability can improve treatment outcomes.
- Other names
- MAGED1 siRNAMAGED-1 siRNAMAGED 1 siRNAsi-MAGED1si-MAGED-1si-MAGED 1
02
Targets
MAGED1 (Melanoma-associated antigen D1)
Beyond the preview
Go deeper on MAGED1 small interfering RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGED1 small interfering RNA.